During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived.
Most hematologists and oncologists in practice today probably learned that the regimen most likely to cure Hodgkin lymphoma is the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine, commonly referred to as ABVD. In the early 1990s ABVD demonstrated improved failure-free survival (but not overall survival) and lower toxicity compared with the older regimen of MOPP (mechlorethamine hydrochloride, vincristine sulfate [Oncovin], procarbazine hydrochloride, and prednisone).
In 2018 things changed when data from the ECHELON-1 trial (NCT01712490) showed that the replacement of bleomycin in the ABVD regimen with brentuximab vedotin (BV-AVD) demonstrated superior progression-free survival (PFS) in patients with advanced-stage Hodgkin lymphoma. Many experts considered BV-AVD to be one standard of care, along with ABVD, but not the only standard of care. However, since 2022, when updated ECHELON-1 results demonstrated that an overall survival difference had emerged between the 2 groups, BV-AVD became the preferred regimen for patients with advanced-stage Hodgkin lymphoma.
During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived. SWOG S1826 (NCT03907488) compared BV-AVD with an investigational arm that replaced BV with nivolumab (Opdivo; N-AVD) in patients with advanced-stage Hodgkin lymphoma. Results of the second interim analysis showed the HR for PFS was 0.48 (P = .0005) in favor of the N-AVD arm. One-year PFS rates in the N-AVD and BV-AVD groups were 94% and 86%, respectively.
Paradoxically, I find these exciting results to be a little disappointing. As BV is clearly one of our better drugs for the disease, I cannot help wonder whether, by leaving it on the shelf, we will be delivering the best regimen for patients with the tools we have. Indeed, one clinical trial (NCT03646123) has already studied the combination of nivolumab, brentuximab vedotin, doxorubicin, and dacarbazine, and demonstrated promising results. Of course, without a randomized trial, we can only speculate whether that regimen would be superior to N-AVD.
But after decades of relatively little progress, against a cancer that, although not the most common, causes the loss of many years of life, we can only be thankful that we live in this era in which our treatment options for patients keep getting better and better.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Overcoming Barriers in Cancer Clinical Trials: A Path Forward for Better Patient Care
April 29th 2024Clinical trials play a pivotal role in developing effective therapies, yet their integration is challenged by issues such as insufficient reimbursement structures, misaligned incentives, physician burnout, and a complex regulatory environment.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More